Title : Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.

Pub. Date : 2021 Jul

PMID : 33894335






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: After median follow-up of 31.0 months, pembrolizumab plus pemetrexed-platinum continued to improve OS (hazard ratio [HR], 0.56; 95% CI, 0.46-0.69), and PFS (HR, 0.49; 95% CI, 0.41-0.59) over placebo plus pemetrexed-platinum regardless of PD-L1 expression. Platinum CD274 molecule Homo sapiens